Thursday, October 13, 2022, 6:00 -7:00 PM EDT; Cambridge, MA, USA
A look at the benefits and challenges of decentralized clinical trials and the implications for their long-term adoption.
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Join PROMETRIKA and guest Ken Getz, MBA, Executive Director of the Tufts Center for the Study of Drug Development, to explore the ongoing experience with decentralized clinical trials (DCTs). Mr. Getz and Chelsey Ryan, PMP, Director, Clinical Operations and Pharmacovigilance at PROMETRIKA, will review data on DCT use and discuss the types of studies most suited for virtual and remote support. Participants in the live webcast will have the opportunity to discuss with Mr. Getz how to advance DCTs in clinical research.
Mr. Getz has enjoyed a 30-year career of providing research and information to clinical trial professionals in the drive to understand and improve clinical research. An internationally recognized expert on clinical trial management practices and trends, Mr. Getz’s studies on protocol design complexity, clinical research efficiency and effectiveness, and the global outsourcing landscape have contributed to an industry-wide understanding of these critical markets. His current research aims to inform the adoption of decentralized clinical trials.
Ms. Ryan’s extensive 12-year background in leading global clinical research projects has given her the knowledge and insight to translate the many needs of trial stakeholders into unified goals. As the industry embraces decentralization, Ms. Ryan continues to examine the best application of DCT methods to optimize each clinical trial.
“We have gained first-hand experience during the pandemic with, and we’re learning much more about how to optimize the use of, decentralized clinical trial solutions. I’m very excited to be sharing Tufts CSDD data to inform best DCT use practices.”
Ken Getz, MBA
Executive Director and Research Professor
“ We are thrilled to have Ken Getz speak about his in-depth research on decentralized trials. We hope you will join us! The evening promises a robust discussion on the future of clinical research and the role DCTs will play.”
Miganush Stepanians, PhD
Founder, President, and CEO
For further information please contact